全文获取类型
收费全文 | 863篇 |
免费 | 43篇 |
国内免费 | 10篇 |
学科分类
医药卫生 | 916篇 |
出版年
2023年 | 15篇 |
2022年 | 32篇 |
2021年 | 37篇 |
2020年 | 27篇 |
2019年 | 24篇 |
2018年 | 35篇 |
2017年 | 28篇 |
2016年 | 31篇 |
2015年 | 39篇 |
2014年 | 27篇 |
2013年 | 39篇 |
2012年 | 46篇 |
2011年 | 45篇 |
2010年 | 28篇 |
2009年 | 26篇 |
2008年 | 57篇 |
2007年 | 50篇 |
2006年 | 47篇 |
2005年 | 42篇 |
2004年 | 35篇 |
2003年 | 17篇 |
2002年 | 14篇 |
2001年 | 19篇 |
2000年 | 17篇 |
1999年 | 11篇 |
1998年 | 8篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1995年 | 5篇 |
1993年 | 2篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 11篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1987年 | 9篇 |
1986年 | 11篇 |
1985年 | 4篇 |
1984年 | 6篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 9篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1925年 | 1篇 |
排序方式: 共有916条查询结果,搜索用时 15 毫秒
1.
Dr. Nermin Yamalik DDS PhD Ugur F. Avcikurt DDS † Feriha Caglayan DDS PhD ‡ Kenan Eratalay DDS PhD § 《Australian dental journal》1993,38(2):108-113
During the treatment of patients with renal failure or renal transplants the most important consideration is to eliminate sources of infection before and after the treatment. Acute or chronic oral infections or bacteraemias resulting from dental procedures may cause serious complications in these patients who already have lowered host resistance caused by immunosuppressant therapy. In order to determine the latest concepts from some international transplantation centres relating to the importance of and the effect of infective sources in the oral cavity, a survey form was prepared which included several questions related to oral foci of infection and renal transplantations.
Results obtained from 22 centres from 12 countries indicated that the majority of the centres included a dental examination in their routine protocol and required completion of any necessary dental treatment before transplantation. However, full agreement among all these centres on the necessity for dental examination as part of the protocol has not yet been reached. 相似文献
Results obtained from 22 centres from 12 countries indicated that the majority of the centres included a dental examination in their routine protocol and required completion of any necessary dental treatment before transplantation. However, full agreement among all these centres on the necessity for dental examination as part of the protocol has not yet been reached. 相似文献
2.
Nerve growth factor (first of three parts). 总被引:7,自引:0,他引:7
W C Mobley A C Server D N Ishii R J Riopelle E M Shooter 《The New England journal of medicine》1977,297(20):1096-1104
3.
Extra-chromosomal telomeric DNA in cells from Atm(-/-) mice and patients with ataxia-telangiectasia 总被引:3,自引:0,他引:3
Hande MP Balajee AS Tchirkov A Wynshaw-Boris A Lansdorp PM 《Human molecular genetics》2001,10(5):519-528
Ataxia-telangiectasia (AT) is an autosomally recessive human genetic disease with pleiotropic defects such as neurological degeneration, immunodeficiency, chromosomal instability, cancer susceptibility and premature aging. Cells derived from AT patients and ataxia-telangiectasia mutated (ATM)-deficient mice show slow growth in culture and premature senescence. ATM, which belongs to the PI3 kinase family along with DNA-PK, plays a major role in signaling the p53 response to DNA strand breaks. Telomere maintenance is perturbed in yeast strains lacking genes homologous to ATM and cells from patients with AT have short telomeres. We examined the length of individual telomeres in cells from ATM(-/-) mice by fluorescence in situ hybridization. Telomeres were extensively shortened in multiple tissues of ATM(-/-) mice. More than the expected number of telomere signals was observed in interphase nuclei of ATM(-/-) mouse fibroblasts. Signals corresponding to 5-25 kb of telomeric DNA that were not associated with chromosomes were also noticed in ATM(-/-) metaphase spreads. Extrachromosomal telomeric DNA was also detected in fibroblasts from AT patients and may represent fragmented telomeres or by-products of defective replication of telomeric DNA. These results suggest a role of ATM in telomere maintenance and replication, which may contribute to the poor growth of ATM(-/-) cells and increased tumor incidence in both AT patients and ATM(-/-) mice. 相似文献
4.
Dean E. Brenner Sherri Galloway John Cooper Richard Noone Kenneth R. Hande 《Cancer chemotherapy and pharmacology》1985,14(2):139-145
Summary We compared doxorubicin and metabolite pharmacokinetic data obtained from thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC) assay of plasma samples from six patients who had been treated with doxorubicin. Duplicate 1-ml samples were extracted with chloroform: isopropanol (1:1) and assayed using a sensitive HPLC system incorporating a dual pump gradient with tetrahydrofuran as the mobile phase and fluorescence detection. Duplicate 1-ml samples from the same specimens were assayed using a modification of a previously described TLC assay. Areas under the curve for doxorubicin by HPLC (3.36±2.30 M · h) and TLC (4.16±2.50 M · h) were not significantly different (P=0.5). Terminal half-life of doxorubicin by HPLC (28.0±6.98 h) and TLC (23.2±7.8) (P=0.29) and the calculated total-body clearances by HPLC (0.55±0.29 l/min) and TLC (0.45±0.23) (P=0.55) were not significantly different. Areas under the curve for doxorubicinol by HPLC (2.75±1.4 M · h) and TLC (2.53±7.1 M · h) (P=0.73) showed no significant differences. HPLC detected a mixed 7-deoxydoxorubicinol aglycone-doxorubicin aglycone peak, 7-deoxydoxorubicin aglycone, and two nonpolar, unidentified metabolites. TLC detected the following aglycone metabolites: doxorubicin aglycone, doxorubicinol aglycone, 7-deoxydoxorubicinol aglycone, an unidentified polar metabolite, and several unidentified nonpolar metabolites. From these data we conclude that HPLC and TLC detect concentrations of doxorubicin and doxorubicinol from human plasma equally well to concentrations of 7.0 nM (4 pmol injected doxorubicin). Aglycones do circulate in human plasma at concentrations above the detection limits of both assays. Doxorubicinol aglycone, which is detected by TLC but not by HPLC, may be formed from artifactual breakdown of doxorubicinol during TLC development. Unidentified nonpolar compounds seen on HPLC and TLC may represent further doxorubicin metabolism than previously described. 相似文献
5.
S. N. Wolff W. W. Grosh K. Prater K. R. Hande 《Cancer chemotherapy and pharmacology》1987,19(3):246-249
Summary VP-16-213 (Etoposide) is an active antineoplastic agent which has undergone extensive evaluation of clinical dose escalation. To corroborate a putative dose-response relationship, we studied, in a modified clonogenic assay, various doses and durations of exposure. VP-16-213 at doses of 0.01, 0.05, 0.10, 0.50, 1.0, 5.0 and 10.0 g/ml, each with exposure durations of 1, 3, 18, and 30 h, was studied in vitro against two human tumor cell lines, MOLT and 9812. The doses and durations of exposure were chosen to approximate some of the pharmacokinetic values achievable in either standard-dose or high-dose clinical studies. The results, summarized as linear regression lines, demonstrate with statistical significance (p<0.03) that there is correlation between dose and cytotoxicity and between dose x duration of exposure (representing the area under the concentration-time curve) and cytotoxicity. Our in vitro data thus support the concept of intensive use of VP-16-213 to maximize antitumor activity. However, how best to accomplish the manipulation of dose and duration of exposure is not yet clear and will be the subject of future clinical investigations.Supported in part by Grant ROI CA39686 from the NIH (KR Hande) 相似文献
6.
7.
Nygren P Hande K Petty KJ Fedgchin M van Dyck K Majumdar A Panebianco D de Smet M Ahmed T Murphy MG Gottesdiener KM Cocquyt V van Belle S 《Cancer chemotherapy and pharmacology》2005,55(6):609-616
Background Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in the clearance of several chemotherapeutic agents. In this study we examined the potential for aprepitant to affect the pharmacokinetics and toxicity of intravenously administered docetaxel, a chemotherapeutic agent that is primarily metabolized by CYP3A4.Methods A total of 11 cancer patients (4 male, 7 female, aged 50–68 years) were enrolled in this multicenter, randomized, open-label, two-period, crossover study. Patients received a single infusion of docetaxel monotherapy, 60–100 mg/m2, on two occasions at least 3 weeks apart. During one of the cycles (treatment A), patients received docetaxel alone. During the alternate cycle (treatment B), they also received aprepitant 125 mg orally 1 h prior to docetaxel infusion (day 1), and a single oral dose of aprepitant 80 mg on days 2 and 3. The pharmacokinetic profile of docetaxel was assessed over 30 h following docetaxel infusion. Blood counts were monitored on days 1, 4, 7, and 14.Results Ten patients completed the study. Concomitant administration of aprepitant did not cause any statistically or clinically significant changes in docetaxel pharmacokinetics. Values for docetaxel alone (treatment A) versus docetaxel with aprepitant (treatment B) were as follows: geometric mean AUC0–last was 3.26 vs 3.17 g h/ml (P>0.25; ratio B/A 0.97); geometric mean AUC0– 3.51 vs 3.39 g h/ml (P>0.25; ratio B/A 0.96); geometric mean Cmax was 3.53 vs 3.37 g/ml (P>0.25; ratio B/A 0.95); and geometric mean plasma clearance was 23.3 vs 24.2 l/h/m2 (P>0.25; ratio B/A 1.04). The corresponding harmonic mean half-life values were 10.1 and 8.5 h. The two treatment regimens had similar tolerability profiles; the median absolute neutrophil count nadirs were 681/mm3 during treatment with docetaxel alone and 975/mm3 during aprepitant coadministration.Conclusions Aprepitant had no clinically significant effect on either the pharmacokinetics or toxicity of standard doses of docetaxel in cancer patients. Aprepitant at clinically recommended doses may have a low potential to affect the pharmacokinetics of intravenous chemotherapeutic agents metabolized by CYP3A4. 相似文献
8.
Nurullah elik Hande Küük Kurtulgan Fatih Klbay Gaffari Tun Aya Kmürlüolu Onur Ta Cemile Ece alar imek Taha nar Yeim Sdar Duman 《Journal of clinical research in pediatric endocrinology》2022,14(4):469
The genetic cause of 46, XY disorder of sex development (DSD) still cannot be determined in about half of the cases. GATA-4 haploinsufficiency is one of the rare causes of DSD in genetic males (46, XY). Twenty-two cases with 46, XY DSD due to GATA-4 haploinsufficiency (nine missense variant, two copy number variation) have been previously reported. In these cases, the phenotype may range from a mild undervirilization to complete female external genitalia. The haploinsufficiency may be caused by a sequence variant or copy number variation (8p23 deletion). The aim of this study was to present two unrelated patients with DSD due to GATA-4 variants and to review the phenotypic and genotypic characteristics of DSD cases related to GATA-4 deficiency. 相似文献
9.
以盆栽试验为主,结合大田生产试验来研究稀土微肥对甘蔗增产增糖的机理。研究结果表明,稀土能提高甘蔗叶片叶绿素含量,改善叶片的超微结构,增加叶肉细胞和维管束鞘细胞的叶绿体数,增加叶肉细胞叶绿体中的基粒数和基粒片层数,增大叶片光合膜面积,能促进根系生长,提高根系活力,促进根系对N、P、K等营养元素的吸收;能提高甘蔗体内K、Ca、Zn、Cu等元素的水平,而相对降低Mn、Na等元素的水平;能提高甘蔗伸长期叶片酸性转化酶活性,降低成熟期叶片酸性转化酶活性,提高伸长期及成熟期叶片中性转化酶活性,协调甘蔗的生长和蔗糖分的积累,能调节细胞的渗透压,维持细胞膜结构和功能的稳定性和完整性,增强细胞壁的伸缩性,提高甘蔗的抗旱性;能改善质膜的透性,提高其选择吸收能力,减轻高浓度Na~+的毒害,提高甘蔗的耐盐能力。 相似文献
10.
INTRODUCTION: The aim of our study was to analyse the role of adrenomedullin (AM) and endothelin-1 (ET-1) in the adaptation of the maternal vascular system in normotensive pregnancy. METHODS: Twenty-eight pregnant women, who were normotensive throughout the duration of their pregnancy, were recruited into the study. Plasma levels of AM and ET-1 at each trimester were measured and the AM/ET-1 ratio was calculated. RESULTS: Our experiment showed a significant decrease in plasma concentrations of AM in the first trimester for the study group (n=28) compared with the non-pregnant control group (n=16). There was also a significant decrease in plasma concentrations of ET-1 in all three trimesters (P<0.05) and a significant increase in the AM/ET-1 ratio in all three trimesters (P<0.05) for the study group compared with the control group. CONCLUSION: An alteration in vascular equilibrium between AM and ET-1, favouring AM, may be a reason why the physiological adaptation of the maternal vascular system to pregnancy occurs during normotensive pregnancy. 相似文献